Abstract:BACKGROUND: The function of the tumor suppressor gene RASSF1A in cancer cells has been detailed in many studies. However, due to the methylation of its promoter, the expression of RASSF1A is missing in most cancers. In the literature, we found that the conclusion regarding the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma was not unified. This study adopts the use of a meta-analysis and bioinformatics to explore the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma.METHODS: Data on melanoma susceptibility were downloaded from the PubMed, Cochrane Library, Web of Science and Google Scholar databases, which were analyzed via a meta-analysis. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). We also used a chi-squared-based Q test to examine the between-study heterogeneity, and used funnel plots to evaluate publication bias. The data on melanoma prognosis, which were analyzed by bioinformatics methods, were downloaded from The Cancer Genome Atlas (TCGA) project. The effect sizes were estimated by measuring the hazard ratios (HRs) with a 95% confidence interval (CI).RESULTS: Our meta-analysis included 10 articles. We found that RASSF1A gene promoter methylation was closely related to melanoma susceptibility (OR = 12.67, 95% CI: 6.16 ∼ 26.05, z = 6.90, P<0.0001 according to a fixed effects model and OR = 9.25, 95% CI: 4.37 ∼ 19.54, z = 5.82, P<0.0001 according to a random effects model). The results of the meta-analysis did not reveal any heterogeneity (tau2 = 0.00; H = 1 [1; 1.55]; I2 = 0% [0%; 58.6%], P = 0.5158) or publication bias (t = 0.87, P = 0.4073 by Egger's test; Z = 0.45, P = 0.6547 by Begg's test); therefore, we believe that the results of our meta-analysis were more reliable. To explore the relationship between RASSF1A gene methylation, the prognosis of melanoma and the clinical features of this cancer type, we used the melanoma DNA methylation data and clinical data from TCGA project. We found that RASSF1A gene promoter methylation and melanoma prognosis did not demonstrate any relationship (HR was 0.94 (95% CI = [0.69; 1.27], P = 0.694) with disease-free survival and 0.74 (95% CI = [0.53; 1.05], P = 0.106) for overall survival), and no significant difference was observed between RASSF1A gene promoter methylation and the clinical-pathological features of melanoma.CONCLUSIONS: In conclusion, the meta-analysis of the data in these articles provides strong evidence that the methylation status of the RASSF1A gene promoter was strongly related to melanoma susceptibility. Our bioinformatics analysis revealed no significant difference between RASSF1A gene promoter methylation and the prognosis and clinical-pathological features of melanoma.

Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.

RASSF1A promoter methylation correlates development, progression, and poor cancer-specific survival of renal cell carcinoma: trial sequential analysis.

Prognostic effects of RASSF1A, BRCA1, APC, and p16 promoter methylation in ovarian cancer: a meta-analysis

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics

The Association Of Ras Association Domain Family Protein1a (Rassf1a) Methylation States And Bladder Cancer Risk: A Systematic Review And Meta-Analysis

Rassf1a Promoter Hypermethylation Is A Strong Biomarker Of Poor Survival In Patients With Salivary Adenoid Cystic Carcinoma In A Chinese Population

Identification Of Epigenetic Aberrant Promoter Methylation Of Rassf1a In Serum Dna And Its Clinicopathological Significance In Lung Cancer

Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer patients

Deletion of OPCML Gene and Promoter Methylation in Ovarian Epithelial Carcinoma

Methylation of Tumor Suppressor Gene RASSF1A and BRCA1 in Primary Epithelial Ovarian Cancer

Analysis of Methylation Status of RASSF1A promoter Region and Transcription Level of Downstream Genes in Non-Small Cell Lung Cancer

Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications.

Detection of Serum RASSF1A Gene Promoter Methylation in Patients with Gastric Cancer

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

An analysis of the relationship between the methylation of RASSF1A gene and gastric cancer

High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions

Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

Methylation Patterns of RASA3 Associated with Clinicopathological Factors in Hepatocellular Carcinoma.

Detection of Rassf1a Promoter Hypermethylation in Serum from Gastric and Colorectal Adenocarcinoma Patients

[Methylation status of RASSF1A gene promoter in upper tract urothelial carcinoma and its clinical significance].